Where translation falls short in practice
June 10, 2026 | Localisation, clinical trial, translation
Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.
Running global clinical trials requires clear communication with participants. Every detail needs to land as intended. But a technically accurate translation may still fall short, creating avoidable barriers for participants and adding clarification burdens for site staff.
This is the gap between translated material and content that is genuinely understood. While standard translation focuses on linguistic accuracy, expert localisation adapts the meaning, context and tone so it works for the intended audience.
Accuracy does not guarantee understanding
So, what if the translation is technically correct but the participant still has to ask the site team what it really means? This is where localisation becomes essential.
It would be easy to assume a correctly translated sentence automatically conveys the intended meaning. In clinical research, this assumption can create challenges.
Before localisation even begins, we carefully craft the master document with the right tone, turning complex medical language into clear, plain English. Right from the start, this approach helps make our materials easier to understand. Once that solid foundation is set, our localisation experts adapt the content for each target language, making sure phrasing and sentence structures flow naturally while preserving the necessary medical accuracy. Ultimately, this process bridges the gap between technical correctness and real participant understanding.
How tone and intent shift across borders
Language is deeply tied to culture. What sounds polite and encouraging in one country might sound demanding or inappropriately casual in another.
For example, in some cultures, participant-facing materials are expected to use highly formal language, while in others a more conversational, approachable style is preferred. If materials written in plain English are directly translated without adapting the tone, they can come across as either too informal or overly authoritative, depending on the context. Localising content carefully adapts not just the words but the underlying intent, making sure it resonates with local expectations and, most importantly, helps foster participant trust.
Why right can still feel wrong
Even with perfect grammar, content can still feel unnatural. Best-practice research on translation and cultural adaptation in clinical studies has long shown that concepts and phrasing may need to be adapted, not just translated, to remain meaningful and relevant for the target audience. A recent study by Gregório et al. (2025) is one of many to evidence this.
Idiomatic expressions or metaphors used to explain how a drug works rarely cross borders intact. A ‘lock and key’ metaphor makes perfect sense to an English speaker, but it might have a totally different meaning in another region.
When trial participants read materials that feel distinctly foreign, they may question if the trial truly understands their needs. It’s vital that every piece of information reads as if it were written specifically for that local participant, in their own cultural context.
Spotting the warning signs
Poor translation can create operational challenges long before participants raise concerns directly. Trial teams may see the impact in added site queries, slower consent processes, misunderstandings around trial requirements and, over time, risks to protocol adherence and retention.
The value of getting it right
Standard translation gets your words across the border, but strategic localisation gets your meaning into the hands of the participant. We pride ourselves on delivering localised clinical trial materials that minimise confusion, reduce operational challenges and keep trials running smoothly.
Recognising where translation falls short is the first step. Next, we’ll look at what effective localisation actually looks like in practice.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Another year, another B!
Louise Jones, Cuttsy+Cuttsy’s Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.
Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director
Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.
Clinical trial considerations: Why supporting HCPs matters…
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.
Clinical trial considerations: Why diversity matters…
Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here’s why diversity matters…
Clinical trial considerations: Why digital matters…
Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.
Clinical trials explained: Why imagery matters…
Recruiting patients for clinical trials is one of pharma’s greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the…
Clinical trials explained: Why health literacy matters…
Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take…
Clinical trials explained: Why iconography matters…
Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial…
Cuttsy+Cuttsy appoints Harriet Karia as Managing Director
Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.
Using generative AI in healthcare comms – our promise to our clients
It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when…